Clinical experience using SolcoTrichovac in the treatment of trichomonas infections in women.

Abstract

A lactobacillus vaccine was administered to 102 women with vaginal trichomonad infections. In about half of these patients a local trichomonacidal treatment using nitroimidazol derivatives was also carried out. After completion of the primary course of treatment 84% of the women were free of symptoms and no trichomonads could be demonstrated; within 1 year this figure had risen to 96%. Re-infections after completion of the primary course of treatment and after booster vaccination occurred in only 4–5% of the cases. The bacterial status of the vagina as described by Jirovec and Peter improved markedly, the degree of improvement being related to the number of vaccine treatments performed. After only one vaccination an improvement from grade V (= trichomoniasis) to grade I or II was seen in 64% of the patients. 6 months after the primary course of treatment the vaginal status of 82% of the women was rated grade I or II, and 6 months after the booster vaccination given after 1 year the corresponding figure was 80%. The lactobacillus vaccine treatment described represents a promising development in the therapy of trichomonad and bacterial infections in women.